Protalix BioTherapeutics Files 8-K on Key Corporate Events
Ticker: PLX · Form: 8-K · Filed: Jul 21, 2025 · CIK: 1006281
| Field | Detail |
|---|---|
| Company | Protalix Biotherapeutics, Inc. (PLX) |
| Form Type | 8-K |
| Filed Date | Jul 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, material-agreement, officer-changes
TL;DR
Protalix BioTherapeutics filed an 8-K on July 21, 2025, detailing a material agreement and changes in directors/officers as of June 13, 2025.
AI Summary
Protalix BioTherapeutics, Inc. filed an 8-K on July 21, 2025, reporting events that occurred on June 13, 2025. The filing includes information on a material definitive agreement, the departure and election of directors and officers, and financial statement disclosures. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing signals significant corporate governance and potential strategic shifts within Protalix BioTherapeutics, impacting investors' understanding of the company's leadership and financial reporting.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting corporate events and does not indicate immediate financial distress or significant new risks.
Key Numbers
- 001-33357 — SEC File Number (Company's SEC filing identifier)
- 65-0643773 — EIN (Employer Identification Number)
Key Players & Entities
- Protalix BioTherapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- June 13, 2025 (date) — Earliest event date
- July 21, 2025 (date) — Report date
FAQ
What specific material definitive agreement was entered into by Protalix BioTherapeutics?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text excerpt.
What changes occurred regarding directors or officers on June 13, 2025?
The filing reports the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with compensatory arrangements for certain officers.
What is the primary business of Protalix BioTherapeutics?
Protalix BioTherapeutics is in the business of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
When is Protalix BioTherapeutics' fiscal year end?
The company's fiscal year ends on December 31.
What is the filing date of this 8-K report?
The 8-K report was filed on July 21, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 21, 2025 regarding Protalix BioTherapeutics, Inc. (PLX).